Xencor and Pfizer Enter into Antibody Technology Licensing Agreement
News Mar 03, 2009
Xencor, Inc. has announced that is has entered into a technology license and evaluation agreement with Pfizer Inc to optimize the performance of therapeutic monoclonal antibodies. Pfizer will apply Xencor’s proprietary Xtend™ antibody half-life prolongation technology and XmAb® ADCC enhancing technology to its antibody drug candidates.
Under the terms of the agreement, Pfizer will have access to Xencor’s antibody optimization technology during a non-exclusive research period for evaluation of the technology in several of its discovery projects. In addition, Pfizer has taken a commercial license to Xencor’s technology for one program.
Xencor will receive an upfront payment from Pfizer and is eligible to receive additional consideration based on Pfizer’s successful commercialization of products that incorporate the Xencor technology. Further details of the agreement were not disclosed.
“We are delighted that a world class leader in the antibody space such as Pfizer will be broadly investigating the use of Xencor’s antibody optimization technology within its R&D organization to potentially enhance specific properties of its therapeutic antibody drug candidates,” commented Bassil Dahiyat, Ph.D., Xencor’s chief executive officer.
“The ability to enhance the pharmaceutical properties of antibody drug molecules and customize this class of drugs for specific therapeutic settings is a central differentiating factor which Xencor will continue to pioneer,” commented James Posada, Ph.D., MBA, Xencor’s acting chief business officer.
Scientists have developed a way to identify the beginning of every gene — known as a translation start site or a start codon — in bacterial cell DNA with a single experiment and, through this method, they have shown that an individual gene is capable of coding for more than one protein.